TREE NEWS update: Fosun Pharma Chairman Chen Yuqing proposed a buyback of the company’s A-shares via centralized bidding, with total funds of no less than 250 million yuan and no more than 500 million yuan. The repurchase price would not exceed 150% of the average price over the 30 trading days before the board approves the plan, and the buyback period would run up to 12 months. The shares are intended for convertible bond conversion, equity incentives and/or employee stock ownership plans.
Fosun Pharma Chairman Proposes A-Share Buyback of 250M-500M Yuan
The significance here lies less in the size of the buyback than in its stated purpose: shares are earmarked for convertible bond conversion and equity incentives, not cancellation, so the float reduction is conditional rather than permanent. That distinction matters for anyone tracking Fosun Pharma's capital structure and for employees covered by the incentive or ownership plans. The open question is whether the proposal clears the board in its current form, since the pricing ceiling is tied to a 30-day average set at approval, and how much of the authorized range is actually executed over the 12-month window.
Generated by AI for reference only.
Share on WeChat
Open WeChat → Scan → then tap "…" to send to a chat or Moments.
Tap "…" in the top-right corner to send to a chat or share to Moments.